Elite Journal of Immunology. Volume 2 Issue 5(2024), Pp. 29-38
https://epjournals.com/journals/EJI

Neonatal Immune Development in the Context of HIV Infection: A Review

Emmanuel Ifeanyi Obeagu[1] and Johnson Okwudili Nweke[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com

[2]Diagnostic Laboratory Unit, Medical Centre, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria, nwekejj@gmail.com

Abstract

The neonatal immune system undergoes a critical period of development characterized by dynamic transitions from innate to adaptive immunity, essential for lifelong immune competence. However, in the context of HIV infection, this developmental trajectory is profoundly altered, presenting unique challenges in immune maturation and response. Vertical transmission of HIV from mother to child further complicates neonatal immune development, exposing infants to viral antigens early in life and disrupting the delicate balance required for immune tolerance and responsiveness. This review examines the intricate interplay between neonatal immune development and HIV infection, highlighting the impact on immune cell populations, cytokine profiles, and the efficacy of antiretroviral therapy (ART) in mitigating immune dysfunction. In the presence of HIV, these developmental pathways are disrupted, potentially leading to impaired immune cell differentiation and reduced functional capacity. HIV infection not only affects peripheral immune responses but also impacts lymphoid tissue architecture and thymic function critical for T cell maturation. The consequences of early viral exposure extend beyond immune dysfunction, influencing susceptibility to opportunistic infections and compromising mucosal immunity, which is pivotal for immune education and tolerance induction. Antiretroviral therapy represents a cornerstone in managing HIV infection, particularly in neonates exposed to the virus. Early initiation of ART is crucial in suppressing viral replication, preserving immune function, and reducing the risk of disease progression. However, the effects of ART on neonatal immune development are multifaceted, influencing immune reconstitution, vaccine responses, and long-term immune competence. Optimizing ART regimens that cross the placenta and achieve therapeutic concentrations in neonatal tissues is essential for maximizing treatment efficacy and improving clinical outcomes in HIV-exposed infants.

Keywords: *Neonatal immune system, HIV, vertical transmission, immune development, immune responses*

Citation: Obeagu EI, Nweke JO. Neonatal Immune Development in the Context of HIV Infection: A Review**.** Elite Journal of Immunology, 2024; 2(5): 29-38

Introduction

The neonatal period represents a critical phase in the development of the immune system, marked by a series of intricate processes that establish both innate and adaptive immunity essential for lifelong health.[1] During this time, the immune system undergoes significant maturation, transitioning from a state of relative immunodeficiency at birth to a stage where it can effectively respond to a wide array of pathogens and establish immune memory.[2] Key aspects of neonatal immune development include the maturation of antigen-presenting cells, the establishment of T and B cell repertoires, and the acquisition of immune tolerance to self-antigens and commensal microorganisms.[3] These processes are finely regulated and influenced by genetic factors, environmental exposures, and maternal immune status. However, the presence of HIV infection profoundly disrupts this developmental trajectory, particularly through vertical transmission from HIV-positive mothers to their infants. Vertical transmission occurs either in utero, during delivery, or through breastfeeding, exposing neonates to HIV and altering their immune landscape from the earliest stages of life. HIV infection poses several challenges to neonatal immune development, including direct viral effects on immune cells, systemic immune activation, and compromised thymic function. These disruptions can lead to impaired immune cell differentiation, skewed cytokine profiles, and increased susceptibility to opportunistic infections, profoundly impacting the infant's ability to mount effective immune responses.[4-8] Vertical transmission of HIV introduces viral antigens to the neonatal immune system at a time when immune tolerance mechanisms are still developing. This early exposure can derail immune tolerance processes, leading to autoimmune tendencies or persistent immune activation. Moreover, the virus can directly infect immune cells such as CD4+ T cells and macrophages, compromising their function and altering immune homeostasis. The interplay between HIV and neonatal immune development underscores the complexity of managing HIV infection in infants, necessitating early diagnosis, prompt initiation of antiretroviral therapy (ART), and careful monitoring of immune responses and viral load dynamics.[9-12] The impact of HIV on neonatal immune development extends beyond immediate immunological responses.[13] Infants exposed to HIV often exhibit delays in the maturation of adaptive immune responses, including deficiencies in memory T cell formation and impaired antibody production.[14] These deficits not only affect the ability to control HIV replication but also heighten susceptibility to other infections, including opportunistic pathogens such as Pneumocystis jirovecii and cytomegalovirus. Furthermore, HIV-mediated immune dysregulation can disrupt gut microbiota composition and integrity, impairing mucosal immunity and exacerbating gastrointestinal complications in neonates.[15]

Antiretroviral therapy has revolutionized the management of pediatric HIV/AIDS by suppressing viral replication and preserving immune function. Early initiation of ART in neonates exposed to HIV is critical in preventing viral dissemination and limiting immune dysfunction. Effective ART regimens that penetrate neonatal tissues and achieve therapeutic concentrations are essential for optimizing treatment outcomes and reducing the long-term sequelae of HIV infection. However, challenges remain in balancing the benefits of ART with potential adverse effects on immune development, such as immune reconstitution syndrome and drug resistance.[16-20] The immune responses of HIV-exposed neonates to routine childhood vaccinations also merit attention, as

compromised immune function may affect vaccine efficacy and the establishment of protective immunity. Strategies to enhance vaccine responses in this population include optimizing vaccination schedules, administering booster doses, and exploring novel vaccine formulations that induce robust immune memory despite underlying immune deficiencies.[21-23] Moreover, the long-term consequences of HIV infection on neonatal immune development are increasingly recognized as survivors transition into adolescence and adulthood. Persistent immune activation, incomplete immune reconstitution despite ART, and increased susceptibility to non-AIDS-related infections underscore the need for lifelong monitoring and multidisciplinary care in HIV-exposed individuals. Comprehensive strategies that integrate immunological assessments, psychosocial support, and adherence to ART are essential for optimizing health outcomes and quality of life in this vulnerable population.[24-27]

Neonatal Immune Development

Neonatal immune development represents a complex and dynamic process essential for establishing immune competence early in life.[28] The immune system at birth is relatively immature compared to that of adults, yet it rapidly undergoes crucial developmental milestones during the neonatal period to achieve functionality capable of responding to a myriad of pathogens encountered in the environment. At birth, neonates possess innate immune defenses that provide immediate protection against pathogens.[29] These include physical barriers like the skin and mucous membranes, as well as innate immune cells such as neutrophils, macrophages, and dendritic cells. However, these cells are functionally immature in neonates, exhibiting reduced phagocytic activity and cytokine production compared to adults. This immaturity can lead to increased susceptibility to certain infections early in life. Adaptive immunity, which involves T and B lymphocytes capable of recognizing specific antigens and forming immunological memory, undergoes critical development during the neonatal period.[30] The thymus, responsible for T cell maturation, is active in neonates but its function is influenced by various factors including gestational age and environmental exposures.[31] Neonates initially rely on maternal antibodies transferred across the placenta (mainly IgG) and through breastfeeding (mainly IgA) for passive immunity against pathogens until their own immune system matures sufficiently to produce these antibodies independently.[32]

The balance between immune activation and tolerance is delicately regulated in neonates to avoid immune responses against self-antigens or harmless environmental antigens.[33] Neonatal immune cells tend to bias towards regulatory mechanisms that promote immune tolerance, such as higher levels of regulatory T cells and reduced pro-inflammatory responses. This balance is crucial for preventing autoimmune diseases and allergic reactions later in life. The gut microbiota also plays a significant role in neonatal immune development.[34] Early colonization of the gut with commensal bacteria influences the maturation and function of the immune system, particularly the development of mucosal immunity. Disruptions in gut microbiota composition, such as those caused by antibiotics or cesarean section delivery, may impact immune development and increase susceptibility to infections or immune-mediated disorders. Factors influencing neonatal immune development extend beyond biological processes to include environmental factors, maternal

health, and nutritional status. Maternal infections during pregnancy, such as HIV, can significantly alter neonatal immune development. Vertical transmission of pathogens can expose neonates to infections early in life, affecting immune maturation and predisposing them to complications.[35-38]

Impact of HIV Infection

The impact of HIV infection on the immune system is profound and multifaceted, particularly when considering its effects on both adults and neonates. In adults, HIV targets CD4+ T cells, which are crucial for coordinating immune responses. By infecting and depleting these cells, HIV progressively undermines the immune system's ability to mount effective defenses against infections and malignancies. This immune deficiency characterizes the progression to AIDS (acquired immunodeficiency syndrome), where individuals become increasingly vulnerable to opportunistic infections and cancers that would typically be controlled by a healthy immune system.[39-43]

In neonates, the impact of HIV infection is equally significant but presents unique challenges. Vertical transmission of HIV from an infected mother to her child can occur during pregnancy, delivery, or through breastfeeding. This early exposure to HIV can disrupt the delicate process of neonatal immune development. Infants born to HIV-positive mothers often exhibit alterations in immune cell populations and function, compromised thymic output, and skewed cytokine profiles towards inflammatory responses. These disruptions can impair the maturation of both innate and adaptive immune responses, rendering neonates more susceptible to infections early in life. Moreover, HIV infection in neonates can have long-term consequences on immune health. Despite advancements in antiretroviral therapy (ART) that effectively suppress viral replication, some infants may experience incomplete immune reconstitution. This phenomenon can lead to persistent immune activation and dysfunction, contributing to ongoing vulnerability to infections even with viral suppression. Furthermore, the disruption of immune maturation pathways by HIV may affect the establishment of immune memory and the ability to respond effectively to vaccinations, potentially compromising long-term immune protection.[44-48] The impact of HIV infection on neonates extends beyond immune dysfunction to affect broader aspects of health and development. HIV-exposed infants may experience growth delays, neurodevelopmental challenges, and increased risks of co-infections and chronic diseases. Early diagnosis and initiation of ART are critical to mitigate these effects, as timely treatment can suppress viral replication, preserve immune function, and improve overall health outcomes. However, challenges remain in optimizing ART regimens for neonates, ensuring adherence to treatment protocols, and addressing long-term complications associated with HIV infection and its treatment.[49-52]

Immune Responses and Antiretroviral Therapy (ART)

Immune responses and antiretroviral therapy (ART) play critical roles in managing HIV infection, particularly in how they interact to influence the progression of the disease and the overall health outcomes of individuals living with HIV/AIDS. Antiretroviral therapy represents the cornerstone of HIV treatment by effectively suppressing viral replication and preserving immune function.

ART typically consists of a combination of medications that target different stages of the HIV lifecycle, including reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, and entry inhibitors. By reducing viral load to undetectable levels in the bloodstream, ART helps restore immune function and prevents the progression to AIDS (acquired immunodeficiency syndrome). This suppression of viral replication is crucial not only for controlling the infection but also for mitigating the ongoing destruction of CD4+ T cells and preserving immune system integrity.[53-54] In individuals living with HIV, ART enables immune reconstitution, characterized by the recovery of CD4+ T cell counts and a reduction in immune activation markers.[55] This restoration of immune function allows for improved responses to infections and vaccinations, enhancing the individual's ability to maintain overall health. Effective ART also helps prevent opportunistic infections, which are a significant cause of morbidity and mortality in untreated HIV infection. However, the immune responses in individuals on ART can vary widely depending on factors such as the timing of treatment initiation, adherence to medication regimens, and the presence of comorbidities.[56] Early initiation of ART, ideally soon after diagnosis, is associated with better immune recovery and improved long-term outcomes. In contrast, delayed initiation of treatment may result in irreversible immune damage and an increased risk of complications.

Despite the benefits of ART, challenges remain in achieving optimal immune restoration in all individuals living with HIV.[57] Some individuals may experience immune dysfunction despite viral suppression, characterized by persistent inflammation, immune activation, and an increased risk of non-AIDS-related illnesses such as cardiovascular disease, kidney disease, and certain cancers. These complications underscore the need for ongoing monitoring of immune function and tailored management strategies to address immune dysregulation in HIV-infected individuals.

Furthermore, the impact of ART on immune responses extends to the realm of vaccinations. Vaccination is an essential component of preventive healthcare for individuals living with HIV, as they are at increased risk of infections due to immune compromise.[58] ART can enhance vaccine responses by improving CD4+ T cell counts and function, thereby increasing the likelihood of developing protective immunity against vaccine-preventable diseases.[59] However, immune responses to vaccines in HIV-infected individuals may still be suboptimal compared to those in HIV-negative individuals, necessitating strategies such as additional vaccine doses or booster shots to achieve adequate protection.

Conclusion

The management of HIV infection requires a comprehensive understanding of its profound impact on immune responses and the pivotal role of antiretroviral therapy (ART) in mitigating these effects. HIV infection disrupts immune function by targeting CD4+ T cells, leading to progressive immune deficiency and increased susceptibility to opportunistic infections and other diseases. ART plays a crucial role in suppressing viral replication, which not only preserves immune function but also allows for immune reconstitution by restoring CD4+ T cell counts and reducing immune activation. The benefits of ART extend beyond viral suppression to include improvements in overall health outcomes and quality of life for individuals living with HIV/AIDS. Early initiation

of ART is associated with better immune recovery and a reduced risk of disease progression to AIDS-related illnesses. However, challenges such as medication adherence, drug resistance, and the persistence of immune dysfunction in some individuals underscore the ongoing need for research and tailored management strategies. Immune responses in HIV-infected individuals on ART can vary widely, influencing susceptibility to infections and responses to vaccinations. Enhancing vaccine responses remains an important goal, as preventive immunizations are critical for reducing the burden of infections in this population.

References

1. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉD, Bhatia J, Hale VL, Baban B. Innate immunity of neonates and infants. Frontiers in immunology. 2018; 9:1759.
2. Goenka A, Kollmann TR. Development of immunity in early life. Journal of Infection. 2015;71: S112-120.
3. Lewis DB, Weitkamp JH, Levy O. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant 2025: 73-159. Elsevier.
4. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
5. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
6. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
7. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
9. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
10. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
11. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine, 2024; 2(1): 1-16
12. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
13. Kuhn L, Meddows-Taylor S, Gray G, Tiemessen C. Human immunodeficiency virus (HIV)–specific cellular immune responses in newborns exposed to HIV in utero. Clinical infectious diseases. 2002;34(2):267-276.
14. Muenchhoff M, Prendergast AJ, Goulder PJ. Immunity to HIV in early life. Frontiers in immunology. 2014; 5:391.

Citation: Obeagu EI, Nweke JO. Neonatal Immune Development in the Context of HIV Infection: A Review**.** Elite Journal of Immunology, 2024; 2(5): 29-38

15. Geng ST, Zhang ZY, Wang YX, Lu D, Yu J, Zhang JB, Kuang YQ, Wang KH. Regulation of gut microbiota on immune reconstitution in patients with acquired immunodeficiency syndrome. Frontiers in microbiology. 2020; 11:594820.
16. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
17. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
18. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26
19. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117
20. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73
21. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
22. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35
23. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59
24. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
25. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
26. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72
27. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
28. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉD, Bhatia J, Hale VL, Baban B. Innate immunity of neonates and infants. Frontiers in immunology. 2018; 9:1759.
29. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nature Reviews Immunology. 2007;7(5):379-390.
30. Pieren DK, Boer MC, de Wit J. The adaptive immune system in early life: The shift makes it count. Frontiers in immunology. 2022; 13:1031924.

Citation: Obeagu EI, Nweke JO. Neonatal Immune Development in the Context of HIV Infection: A Review**.** Elite Journal of Immunology, 2024; 2(5): 29-38

31. Rackaityte E, Halkias J. Mechanisms of fetal T cell tolerance and immune regulation. Frontiers in immunology. 2020; 11:588.
32. Sereme Y, Toumi E, Saifi E, Faury H, Skurnik D. Maternal immune factors involved in the prevention or facilitation of neonatal bacterial infections. Cellular Immunology. 2024; 395:104796.
33. Zhang X, Zhivaki D, Lo-Man R. Unique aspects of the perinatal immune system. Nature Reviews Immunology. 2017;17(8):495-507.
34. Sanidad KZ, Zeng MY. Neonatal gut microbiome and immunity. Current opinion in microbiology. 2020; 56:30-37.
35. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
36. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
37. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
38. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
39. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
40. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
41. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005

Citation: Obeagu EI, Nweke JO. Neonatal Immune Development in the Context of HIV Infection: A Review**.** Elite Journal of Immunology, 2024; 2(5): 29-38

42. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
43. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
44. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
45. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
46. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
47. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
48. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
49. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
50. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
51. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies

Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.

52. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
53. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
54. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
55. Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunological reviews. 2013;254(1):343-354.
56. Misgena DK. The pattern of immunologic and virologic responses to Highly Active Antiretroviral Treatment (HAART): Does success bring further challenges? Ethiopian Journal of Health Development. 2011;25(1):61-70.
57. Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent SJ. Functional cure of HIV: the scale of the challenge. Nature Reviews Immunology. 2019;19(1):45-54.
58. Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, Ho A, Hunter M, Ladhani S, Lawton M, MacMahon E. British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015. HIV medicine. 2016;17(53):S2-81.
59. Laupèze B, Del Giudice G, Doherty MT, Van der Most R. Vaccination as a preventative measure contributing to immune fitness. npj Vaccines. 2021;6(1):93.